231 related articles for article (PubMed ID: 34993609)
1. The clinical consequences of functional adrenal uptake in the absence of cross-sectional mass on FDG-PET/CT in oncology patients.
Hsiao R; Chow A; Kluijfhout WP; Bongers PJ; Verzijl R; Metser U; Veit-Haibach P; Pasternak JD
Langenbecks Arch Surg; 2022 Jun; 407(4):1677-1684. PubMed ID: 34993609
[TBL] [Abstract][Full Text] [Related]
2. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
3. Characterization of lipid-rich adrenal tumors by FDG PET/CT: Are they hormone-secreting or not?
Takanami K; Kaneta T; Morimoto R; Satoh F; Nakamura Y; Takase K; Takahashi S
Ann Nucl Med; 2014 Feb; 28(2):145-53. PubMed ID: 24272068
[TBL] [Abstract][Full Text] [Related]
4. Utility of FDG PET/CT in the Characterization of Sinonasal Neoplasms: Analysis of Standardized Uptake Value Parameters.
Ozturk K; Gencturk M; Caicedo-Granados E; Li F; Cayci Z
AJR Am J Roentgenol; 2018 Dec; 211(6):1354-1360. PubMed ID: 30300005
[TBL] [Abstract][Full Text] [Related]
5. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of
Altinmakas E; Hobbs BP; Ye H; Grubbs EG; Perrier ND; Prieto VG; Lee JE; Ng CS
Abdom Radiol (NY); 2017 Feb; 42(2):577-584. PubMed ID: 27665482
[TBL] [Abstract][Full Text] [Related]
8. [Use of 18F-FDG-positron emission tomography in presurgical evaluation of nonspecific or suspectious adrenal masses in non-oncologic patients].
Pavón-Paz I; Rosado-Sierra JA; Balsa-Bretón MÁ; Guijarro-Armas G; Merino-Viveros M; Penín-Gonzalez FJ
Med Clin (Barc); 2016 Feb; 146(3):104-7. PubMed ID: 26343158
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
11. Predicting malignancy in patients with adrenal tumors using
Vos EL; Grewal RK; Russo AE; Reidy-Lagunes D; Untch BR; Gavane SC; Boucai L; Geer E; Gopalan A; Chou JF; Capanu M; Strong VE
J Surg Oncol; 2020 Dec; 122(8):1821-1826. PubMed ID: 32914407
[TBL] [Abstract][Full Text] [Related]
12. High False Positivity in Positron Emission Tomography is a Potential Diagnostic Pitfall in Patients with Suspected Adrenal Metastasis.
Lang BH; Cowling BJ; Li JY; Wong KP; Wan KY
World J Surg; 2015 Aug; 39(8):1902-8. PubMed ID: 25809060
[TBL] [Abstract][Full Text] [Related]
13. Adrenal findings in FDG-PET: analysis of a cohort of 1021 patients from a cancer center.
Maciel J; Cavaco D; Fraga D; Donato S; Simões H; Sousa R; Simões-Pereira J
Hormones (Athens); 2023 Mar; 22(1):131-138. PubMed ID: 36477790
[TBL] [Abstract][Full Text] [Related]
14. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.
Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D
J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG-PET/CT Evaluation of Indeterminate Adrenal Masses in Noncancer Patients.
He X; Caoili EM; Avram AM; Miller BS; Else T
J Clin Endocrinol Metab; 2021 Apr; 106(5):1448-1459. PubMed ID: 33524123
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment quantitative
Gencturk M; Ozturk K; Koksel Y; Li F; Cayci Z
Clin Imaging; 2019; 53():17-24. PubMed ID: 30308429
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of unenhanced computed tomography and
Delivanis DA; Bancos I; Atwell TD; Schmit GD; Eiken PW; Natt N; Erickson D; Maraka S; Young WF; Nathan MA
Clin Endocrinol (Oxf); 2018 Jan; 88(1):30-36. PubMed ID: 28815667
[TBL] [Abstract][Full Text] [Related]
18. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning.
Han SJ; Kim TS; Jeon SW; Jeong SJ; Yun M; Rhee Y; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
Int J Clin Pract; 2007 May; 61(5):802-9. PubMed ID: 17343665
[TBL] [Abstract][Full Text] [Related]
19. Risk stratification of adrenal masses by [
Salgues B; Guerin C; Amodru V; Pattou F; Brunaud L; Lifante JC; Mirallié E; Sahakian N; Castinetti F; Loundou A; Baumstarck K; Sebag F; Taïeb D
Clin Endocrinol (Oxf); 2021 Feb; 94(2):133-140. PubMed ID: 32978795
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of
Kim SJ; Lee SW; Pak K; Kim IJ; Kim K
Br J Radiol; 2018 Jun; 91(1086):20170520. PubMed ID: 29327944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]